Condition
Diarrhea-predominant Irritable Boewl Syndrome
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Early P 1 (1)
P 3 (1)
Trial Status
Unknown1
Not Yet Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT06753890Phase 3Not Yet RecruitingPrimary
Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)
NCT04312477Early Phase 1UnknownPrimary
Efficacy and Safety of Modified Gegen Qinlian Decoction for Diarrhea-predominant Irritable Boewl Syndrome
Showing all 2 trials